Cartesian Therapeutics 报告重症肌无力患者有显着改善，计划进行 3 期试验。 Cartesian Therapeutics reports significant improvement in myasthenia gravis patients, plans Phase 3 trial.

Cartesian Therapeutics 报告了 Descartes-08（一种治疗重症肌无力）的 2b 期试验的积极结果，显示患者的日常生活活动有显着改善。 Cartesian Therapeutics reported positive results from a Phase 2b trial for Descartes-08, a treatment for myasthenia gravis, showing significant improvements in patients' daily living activities. 参加培训者在四个月的时间里,MG-ADL的分数减少了5.5个百分点,答复期限最长为一年。 Participants experienced a 5.5-point reduction in MG-ADL scores at four months, with responses lasting up to a year. 该公司的股票在市场前上升了5%以上,计划在2025年初进行第三阶段研究。 The company's stock rose over 5% pre-market, and a Phase 3 study is planned for early 2025.